Stryker has received FDA 510(k) clearance for Sonopet 3, its latest ultrasonic bone and soft tissue removal platform developed with surgeon input. The device offers enhanced power, precision, and versatility, featuring new technologies like RISE for integrated surgical workflows and Pulse Control for better tissue resection. Clinical use is expected to start in October, with a full commercial launch planned for later this fall. This advancement aims to improve surgical performance and workflow efficiency in neurosurgery.
Stryker Corporation (SYK) shares are trading at USD 284.97 with a modest gain of 0.83% as of Oct 14, 2026 20:11 WIB on Pluang. Despite the recent launch of Sonopet 3 promising enhanced surgical precision, Pluang order activity shows a strong sell sentiment at 98%. The stock remains well below its 52-week high of USD 388.35, indicating room for market movement following this new product development.
